DM
PRME icon

Deerfield Management’s Prime Medicine PRME Stock Holding History

Deerfield Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-896,960
Closed -$3.47M – 354
2024
Q3 		$3.47M Hold
896,960
– – 0.05% 73
2024
Q2 		$4.61M Buy
896,960
+11,646
+1% +$70.6K 0.08% 71
2024
Q1 		$6.2M Hold
885,314
– – 0.11% 70
2023
Q4 		$7.84M Hold
885,314
– – 0.14% 56
2023
Q3 		$8.45M Hold
885,314
– – 0.19% 61
2023
Q2 		$13M Hold
885,314
– – 0.28% 64
2023
Q1 		$10.9M Hold
885,314
– – 0.24% 71
2022
Q4 		$16.4M Buy
+885,314
New +$16M 0.34% 64

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deerfield Management's PRME Position: Q4 2024 in Review

Deerfield Management sold out of Prime Medicine (PRME) in Q4 2024, closing a stake of 896,960 shares — an estimated $3.47M sold.

Deerfield Management first reported a position in PRME in Q4 2022 and held it in 8 quarters. The position peaked at $16.4M in Q4 2022. 131 funds tracked by Wall St. Rank hold PRME as of Q4 2024.

  • Deerfield Management reported no remaining Prime Medicine position as of Q4 2024 after selling out during the quarter.
  • Deerfield Management sold 896,960 Prime Medicine shares in Q4 2024, an estimated $3.47M.
  • Deerfield Management first reported a position in Prime Medicine in Q4 2022 and held it in 8 quarters.
  • Deerfield Management's Prime Medicine position peaked at $16.4M in Q4 2022.
  • 131 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2024.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.